Pfizer: 3 Key Takeaways for Long-Term Investors
· fool.com · popularity 18/100 · 0 similar stories today · Breaking & World News (World News & Media)
Read the original at fool.com →
Summary
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue. On …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 12.